10-K – Annual report [Section 13 and 15(d), not S-K Item 405]

Cytokinetics has filed a 10-K – Annual report [Section 13 and 15(d), not S-K Item 405] with the U.S. Securities and Exchange Commission (Filing, 10-K, Cytokinetics, 2018, MAR 5, 2018, View Source [SID1234524373]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

10-K – Annual report [Section 13 and 15(d), not S-K Item 405]

Vericel has filed a 10-K – Annual report [Section 13 and 15(d), not S-K Item 405] with the U.S. Securities and Exchange Commission (Filing, 10-K, Vericel, 2018, MAR 5, 2018, View Source [SID1234524372]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

10-K – Annual report [Section 13 and 15(d), not S-K Item 405]

Ophthotech has filed a 10-K – Annual report [Section 13 and 15(d), not S-K Item 405] with the U.S. Securities and Exchange Commission (Filing, 10-K, Ophthotech, 2018, MAR 5, 2018, View Source [SID1234524363]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

6-K – Report of foreign issuer [Rules 13a-16 and 15d-16]

On February 27, 2018 Oncolytics Biotech Inc. (TSX: ONC) (OTCQX: ONCYF), a biotech company developing REOLYSIN, also known as pelareorep, an intravenously delivered immuno-oncolytic virus that activates the innate and adaptive immune systems to turn "cold" tumors "hot", reported that it will present at the 2018 Precision: Breast Cancer World R&D Summit. Dr. Andres Gutierrez, Oncolytics’ Chief Medical Officer, will present at 3:30 pm ET on March 6, 2018 at The Royal Sonesta Boston Hotel (Filing, 6-K, Oncolytics Biotech, MAR 5, 2018, View Source [SID1234524420]). The conference takes place on March 6th and 7th in Boston, MA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Gutierrez will present on the scientific rationale for treating breast cancer therapy with an intravenous reovirus as part of the conference’s Immunotherapies in Breast Cancer presentations.

"This conference provides the opportunity to address a world class audience of scientists, clinicians and business leaders from pharma, biotech and academia, focused on our lead indication of metastatic breast cancer," said Dr. Gutierrez. "We look forward to sharing insights from our clinical development activities and plans, as well as networking with leaders in this space to learn of other cutting-edge treatments for breast cancer patients."

Jounce Therapeutics to Present at Cowen and Company 38th Annual Health Care Conference

On March 5, 2018 Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers for patient enrichment, reported that Richard Murray, Ph.D., chief executive officer and president of Jounce, will present at the Cowen and Company 38th Annual Health Care Conference on Monday, March 12, 2018 at 4:50 PM ET in Boston, MA (Press release, Jounce Therapeutics, MAR 5, 2018, View Source;p=RssLanding&cat=news&id=2336132 [SID1234524972]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available by visiting "Events and Presentations" in the Investors and Media section of Jounce’s website at www.jouncetx.com. A replay of the webcast will be archived for 30 days following the presentation.